Global PEGylated Proteins Market Growth 2019-2024

  • receipt Report ID : 180016
  • calendar_today Published On: Jul, 2019
  • file_copy Pages: 135
  • list Pharmaceuticals and Healthcare

PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s.

The threat of substitutes arises when there are similar products developed by competitors which satisfy the market needs. When consumers have access to substitute products which can satisfy their market needs, then manufacturers and suppliers lose their bargaining power. Consumers are able to purchase competitor's products if they are not satisfied with product price or quality. In order for suppliers to tackle the challenge of threat of substitutes, they have to innovate products which meet the needs of their target market segments.

According to this study, over the next five years the PEGylated Proteins market will register a 3.9% CAGR in terms of revenue, the global market size will reach US$ 3910 million by 2024, from US$ 3230 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PEGylated Proteins business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of PEGylated Proteins market by product type, application, key manufacturers and key regions and countries.

This study considers the PEGylated Proteins value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.

Colony Stimulating Factors

Interferons

Erythropoietin (EPO)

Recombinant Factor Viii

Monoclonal Antibodies

Others

Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.

Cancer Treatment

Hepatitis

Chronic Kidney Disease

Leukemia

SCID

Rheumatoid Arthritis & Crohn's Disease

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Spain

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

ENZON Pharmaceuticals

Merck Sharp & Dohme

Roche

Pfizer

Amgen

UCB

Crealta (Savient)

...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global PEGylated Proteins consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.

To understand the structure of PEGylated Proteins market by identifying its various subsegments.

Focuses on the key global PEGylated Proteins manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the PEGylated Proteins with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of PEGylated Proteins submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

2019-2024 Global PEGylated Proteins Consumption Market Report

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global PEGylated Proteins Consumption 2014-2024

2.1.2 PEGylated Proteins Consumption CAGR by Region

2.2 PEGylated Proteins Segment by Type

2.2.1 Colony Stimulating Factors

2.2.2 Interferons

2.2.3 Erythropoietin (EPO)

2.2.4 Recombinant Factor Viii

2.2.5 Monoclonal Antibodies

2.2.6 Others

2.3 PEGylated Proteins Consumption by Type

2.3.1 Global PEGylated Proteins Consumption Market Share by Type (2014-2019)

2.3.2 Global PEGylated Proteins Revenue and Market Share by Type (2014-2019)

2.3.3 Global PEGylated Proteins Sale Price by Type (2014-2019)

2.4 PEGylated Proteins Segment by Application

2.4.1 Cancer Treatment

2.4.2 Hepatitis

2.4.3 Chronic Kidney Disease

2.4.4 Leukemia

2.4.5 SCID

2.4.6 Rheumatoid Arthritis & Crohn's Disease

2.4.7 Others

2.5 PEGylated Proteins Consumption by Application

2.5.1 Global PEGylated Proteins Consumption Market Share by Application (2014-2019)

2.5.2 Global PEGylated Proteins Value and Market Share by Application (2014-2019)

2.5.3 Global PEGylated Proteins Sale Price by Application (2014-2019)

3 Global PEGylated Proteins by Players

3.1 Global PEGylated Proteins Sales Market Share by Players

3.1.1 Global PEGylated Proteins Sales by Players (2017-2019)

3.1.2 Global PEGylated Proteins Sales Market Share by Players (2017-2019)

3.2 Global PEGylated Proteins Revenue Market Share by Players

3.2.1 Global PEGylated Proteins Revenue by Players (2017-2019)

3.2.2 Global PEGylated Proteins Revenue Market Share by Players (2017-2019)

3.3 Global PEGylated Proteins Sale Price by Players

3.4 Global PEGylated Proteins Manufacturing Base Distribution, Sales Area, Product Types by Players

3.4.1 Global PEGylated Proteins Manufacturing Base Distribution and Sales Area by Players

3.4.2 Players PEGylated Proteins Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 PEGylated Proteins by Regions

4.1 PEGylated Proteins by Regions

4.1.1 Global PEGylated Proteins Consumption by Regions

4.1.2 Global PEGylated Proteins Value by Regions

4.2 Americas PEGylated Proteins Consumption Growth

4.3 APAC PEGylated Proteins Consumption Growth

4.4 Europe PEGylated Proteins Consumption Growth

4.5 Middle East & Africa PEGylated Proteins Consumption Growth

5 Americas

5.1 Americas PEGylated Proteins Consumption by Countries

5.1.1 Americas PEGylated Proteins Consumption by Countries (2014-2019)

5.1.2 Americas PEGylated Proteins Value by Countries (2014-2019)

5.2 Americas PEGylated Proteins Consumption by Type

5.3 Americas PEGylated Proteins Consumption by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC PEGylated Proteins Consumption by Countries

6.1.1 APAC PEGylated Proteins Consumption by Countries (2014-2019)

6.1.2 APAC PEGylated Proteins Value by Countries (2014-2019)

6.2 APAC PEGylated Proteins Consumption by Type

6.3 APAC PEGylated Proteins Consumption by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe PEGylated Proteins by Countries

7.1.1 Europe PEGylated Proteins Consumption by Countries (2014-2019)

7.1.2 Europe PEGylated Proteins Value by Countries (2014-2019)

7.2 Europe PEGylated Proteins Consumption by Type

7.3 Europe PEGylated Proteins Consumption by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Spain

7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa PEGylated Proteins by Countries

8.1.1 Middle East & Africa PEGylated Proteins Consumption by Countries (2014-2019)

8.1.2 Middle East & Africa PEGylated Proteins Value by Countries (2014-2019)

8.2 Middle East & Africa PEGylated Proteins Consumption by Type

8.3 Middle East & Africa PEGylated Proteins Consumption by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

10.2 PEGylated Proteins Distributors

10.3 PEGylated Proteins Customer

11 Global PEGylated Proteins Market Forecast

11.1 Global PEGylated Proteins Consumption Forecast (2019-2024)

11.2 Global PEGylated Proteins Forecast by Regions

11.2.1 Global PEGylated Proteins Forecast by Regions (2019-2024)

11.2.2 Global PEGylated Proteins Value Forecast by Regions (2019-2024)

11.2.3 Americas Consumption Forecast

11.2.4 APAC Consumption Forecast

11.2.5 Europe Consumption Forecast

11.2.6 Middle East & Africa Consumption Forecast

11.3 Americas Forecast by Countries

11.3.1 United States Market Forecast

11.3.2 Canada Market Forecast

11.3.3 Mexico Market Forecast

11.3.4 Brazil Market Forecast

11.4 APAC Forecast by Countries

11.4.1 China Market Forecast

11.4.2 Japan Market Forecast

11.4.3 Korea Market Forecast

11.4.4 Southeast Asia Market Forecast

11.4.5 India Market Forecast

11.4.6 Australia Market Forecast

11.5 Europe Forecast by Countries

11.5.1 Germany Market Forecast

11.5.2 France Market Forecast

11.5.3 UK Market Forecast

11.5.4 Italy Market Forecast

11.5.5 Russia Market Forecast

11.5.6 Spain Market Forecast

11.6 Middle East & Africa Forecast by Countries

11.6.1 Egypt Market Forecast

11.6.2 South Africa Market Forecast

11.6.3 Israel Market Forecast

11.6.4 Turkey Market Forecast

11.6.5 GCC Countries Market Forecast

11.7 Global PEGylated Proteins Forecast by Type

11.8 Global PEGylated Proteins Forecast by Application

12 Key Players Analysis

12.1 ENZON Pharmaceuticals

12.1.1 Company Details

12.1.2 PEGylated Proteins Product Offered

12.1.3 ENZON Pharmaceuticals PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.1.4 Main Business Overview

12.1.5 ENZON Pharmaceuticals News

12.2 Merck Sharp & Dohme

12.2.1 Company Details

12.2.2 PEGylated Proteins Product Offered

12.2.3 Merck Sharp & Dohme PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.2.4 Main Business Overview

12.2.5 Merck Sharp & Dohme News

12.3 Roche

12.3.1 Company Details

12.3.2 PEGylated Proteins Product Offered

12.3.3 Roche PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.3.4 Main Business Overview

12.3.5 Roche News

12.4 Pfizer

12.4.1 Company Details

12.4.2 PEGylated Proteins Product Offered

12.4.3 Pfizer PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.4.4 Main Business Overview

12.4.5 Pfizer News

12.5 Amgen

12.5.1 Company Details

12.5.2 PEGylated Proteins Product Offered

12.5.3 Amgen PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.5.4 Main Business Overview

12.5.5 Amgen News

12.6 UCB

12.6.1 Company Details

12.6.2 PEGylated Proteins Product Offered

12.6.3 UCB PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.6.4 Main Business Overview

12.6.5 UCB News

12.7 Crealta (Savient)

12.7.1 Company Details

12.7.2 PEGylated Proteins Product Offered

12.7.3 Crealta (Savient) PEGylated Proteins Sales, Revenue, Price and Gross Margin (2017-2019)

12.7.4 Main Business Overview

12.7.5 Crealta (Savient) News

...

13 Research Findings and Conclusion

List of Tables and Figures

Figure Picture of PEGylated Proteins

Table Product Specifications of PEGylated Proteins

Figure PEGylated Proteins Report Years Considered

Figur

Please fill the form below, to recieve the report sample


+1